履职一年间丨让重离子治疗更“亲民” 今年两会他带来这些建议

Core Viewpoint - The focus is on the development and clinical application of heavy ion accelerators in China, emphasizing the need for improved technology and market integration to better serve society and benefit patients [1][10]. Group 1: Industry Development - The heavy ion accelerator is a crucial tool for nuclear physics research, materials science, and cancer treatment, with ongoing efforts to enhance its domestic development and application [1]. - A high-tech company in Lanzhou is responsible for the full-chain manufacturing of domestic medical heavy ion devices, facing challenges in technology breakthroughs and market promotion [1][3]. - The heavy ion industry is becoming more complete, with a call for the introduction of social capital into the medical sector to integrate private and public funding into the national healthcare system [3][5]. Group 2: Clinical Application - Currently, 14 medical heavy ion accelerators have been promoted, providing precise treatment for over 3,600 patients, but further efforts are needed in miniaturization, large-scale promotion, and industry chain collaboration [6]. - The first domestically developed medical heavy ion accelerator has completed over 2,400 treatments for difficult tumors, showcasing significant progress in cancer treatment [6][8]. - Despite advancements, challenges remain, including high treatment costs, insufficient intelligence in operations, and the need for broader accessibility [8][10]. Group 3: Policy Recommendations - There is a significant gap in precision radiotherapy in China, necessitating stronger product development and market expansion to meet demand [5][10]. - Suggestions include promoting policies to support high-end medical equipment and improving the medical insurance system to alleviate the financial burden on patients [8][10]. - The development of large scientific devices is seen as a potential engine for innovation, with a focus on accelerating research and improving cost-effectiveness to benefit the public [10][12].